Authors
Latest:
Dr. Villanueva on Eliminating Tumor Heterogeneity in Patients With HCCAugusto Villanueva, MD, an assistant professor of the Division of Liver Diseases at the Tisch Cancer Institute of Icahn School of Medicine at Mount Sinai, discusses mutations and gene signatures for patients with hepatocellular carcinoma, a topic he presented at the 2020 Gastrointestinal Cancers Symposium.
Latest:
Dr. Villanueva on Challenges For Liquid Biopsies in HCCAugusto Villanueva, MD, PhD, assistant professor, Icahn School of Medicine, discusses remaining challenges with liquid biopsies in hepatocellular carcinoma.
Latest:
Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?A retrospective experience suggests that early glottic cancer treated with HRT results in a higher incidence of acute toxicity without improved control compared to CRT delivered in an appropriate OTT.
Latest:
Researchers Investigate Increased Incidence of Thyroid Cancer in CaliforniaTo investigate the possibility of environmental impacts as a predisposition for thyroid cancer, researchers sought to identify counties in California with possible geographic clustering of advanced thyroid cancer cases.
Latest:
Parotid Node Metastases in Locally Advanced Nasopharyngeal and Oropharyngeal Cancer: Implications for Radiotherapy Target Volume DelineationThe ipsilateral parotidean nodes may be at risk of metastatic involvement when bulky ipsilateral level II metastases and multilevel nodal disease are co-existent, possibly due to retrograde lymphatic drainage.
Latest:
Dr. Grothey on the Potential Role of ctDNA as a Marker for Rechallenging Treatment in CRCAxel Grothey, MD, discusses the potential utility of circulating tumor DNA as a marker for rechallenging patients with treatment in colorectal cancer.
Latest:
Open Questions and Future Directions in mCRCExperts in CRC discuss questions and management of mCRC.
Latest:
Dr Hauschild on the Role of Adjuvant/Neoadjuvant Therapy in Melanoma ManagementAxel Hauschild, MD, PhD, discusses the role of adjuvant and neoadjuvant therapy in melanoma, highlighting the utility of perioperative approaches.
Latest:
Long-Term Follow up for Adjuvant Dabrafenib Plus Trametinib in Stage III BRAF-Mutated Melanoma: Final Results of the COMBI-AD StudyCOMBI-AD (NCT01682083) evaluated dabrafenib plus trametinib for patients with BRAF-mutated AJCC-stage III melanoma, and here the final results for RFS, distant-metastasis-free survival and overall survival are presented.
Latest:
Dr. Hoos Discusses the Next Steps for IpilimumabDr. Axel Hoos medical lead at Bristol-Myers Squibb Discusses the Next Steps for Ipilimumab
Latest:
Dr. Hamdan on Choosing Among ABVD Versus A+AVD in Hodgkin LymphomaAyad Hamdan, MD, discusses factors to consider when choosing between brentuximab vedotin (Adcetris), doxorubicin, vinblastine, and dacarbazine versus AVD plus bleomycin in patients with Hodgkin lymphoma.
Latest:
Dr. Tefferi on the Toxicity Profile of ImetelstatAyalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the toxicity of imetelstat in patients with myelofibrosis.
Latest:
Dr. Namakydoust on the Use of Next-Generation Sequencing in Lung CancerAzadeh Namakydoust, MD, FACP, thoracic oncologist, Memorial Sloan Kettering Cancer Center, discusses the use of next-generation sequencing (NGS) in lung cancer.
Latest:
Dr. Nazha on the Potential Role of Ropeginterferon Alfa-2b in Polycythemia VeraAziz Nazha, MD, discusses the potential role of ropeginterferon alfa-2b in polycythemia vera.
Latest:
Women in Oncology: Leukemia Therapies in Humans, for HumansJudith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..
Latest:
Unmet Needs in High-Risk MDSThe panel of experts highlight promising clinical trials for the treatment of myelodysplastic syndrome.
Latest:
Approaches to Postmastectomy Breast Reconstruction Are EvolvingEmerging evidence shows that immediate autologous breast reconstruction can tolerate radiotherapy better than previously thought in select cases.
Latest:
Sentinel Lymph Node Mapping in Endometrial CancerSentinel lymph node mapping shows promise in the management of endometrial cancer, especially if applied using a rigorous staging and treatment algorithm.
Latest:
Dr. Konety on Guidelines for the Management of Bladder CancerBadrinath Konety, MD, MBA, department chair, Department of Urology, University of Minnesota, discusses the guidelines for the management of patients with bladder cancer.
Latest:
Future Directions in ALK-Positive and BRAF-Positive NSCLC ManagementPanelists discuss how advancements in targeted therapies and personalized medicine are crucial for addressing the pressing unanswered questions in the management of ALK-positive and BRAF-positive cancers.
Latest:
Optimizing the Selection of Novel Therapy for Patients With Advanced NSCLCClosing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.
Latest:
Dr. Arun on Immunogenicity in Triple-Negative Breast CancerBanu Arun, MD, professor in the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses immunogenicity in triple-negative breast cancer (TNBC).
